Equities analysts expect Assembly Biosciences Inc (NASDAQ:ASMB) to report $3.21 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Assembly Biosciences’ earnings, with estimates ranging from $3.20 million to $3.22 million. Assembly Biosciences posted sales of $2.66 million during the same quarter last year, which suggests a positive year over year growth rate of 20.7%. The firm is scheduled to report its next quarterly earnings report on Wednesday, November 7th.

According to Zacks, analysts expect that Assembly Biosciences will report full-year sales of $13.05 million for the current fiscal year, with estimates ranging from $12.00 million to $13.60 million. For the next financial year, analysts expect that the business will post sales of $25.90 million per share, with estimates ranging from $12.87 million to $63.00 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($1.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.88) by ($0.42). The business had revenue of $3.22 million during the quarter, compared to analyst estimates of $3.30 million. Assembly Biosciences had a negative net margin of 457.20% and a negative return on equity of 66.34%.

Several analysts have recently weighed in on ASMB shares. ValuEngine raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Zacks Investment Research raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, July 10th. B. Riley dropped their price target on shares of Assembly Biosciences to $45.00 and set a “neutral” rating for the company in a research note on Tuesday, May 8th. Robert W. Baird started coverage on shares of Assembly Biosciences in a research note on Wednesday, August 8th. They issued an “outperform” rating and a $74.00 price target for the company. Finally, BidaskClub cut shares of Assembly Biosciences from a “sell” rating to a “strong sell” rating in a research note on Friday, July 13th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $63.20.

ASMB stock traded up $0.51 during mid-day trading on Monday, reaching $38.35. The company’s stock had a trading volume of 75,934 shares, compared to its average volume of 227,848. The company has a market cap of $933.38 million, a price-to-earnings ratio of -15.91 and a beta of 0.86. Assembly Biosciences has a fifty-two week low of $25.91 and a fifty-two week high of $67.36.

In related news, Director William R. Ringo sold 1,000 shares of the stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $38.50, for a total transaction of $38,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Derek A. Small acquired 2,400 shares of the stock in a transaction that occurred on Thursday, July 19th. The shares were bought at an average cost of $41.48 per share, with a total value of $99,552.00. Following the transaction, the chief executive officer now directly owns 668,091 shares in the company, valued at approximately $27,712,414.68. The disclosure for this purchase can be found here. Corporate insiders own 18.20% of the company’s stock.

Several large investors have recently bought and sold shares of ASMB. TIAA CREF Investment Management LLC boosted its position in shares of Assembly Biosciences by 46.8% during the 4th quarter. TIAA CREF Investment Management LLC now owns 72,331 shares of the biopharmaceutical company’s stock worth $3,273,000 after purchasing an additional 23,064 shares during the period. MetLife Investment Advisors LLC purchased a new position in shares of Assembly Biosciences during the 4th quarter worth approximately $326,000. Rhumbline Advisers boosted its position in shares of Assembly Biosciences by 17.8% during the 1st quarter. Rhumbline Advisers now owns 15,125 shares of the biopharmaceutical company’s stock worth $743,000 after purchasing an additional 2,289 shares during the period. Victory Capital Management Inc. boosted its position in shares of Assembly Biosciences by 263.7% during the 1st quarter. Victory Capital Management Inc. now owns 122,580 shares of the biopharmaceutical company’s stock worth $6,024,000 after purchasing an additional 88,880 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Assembly Biosciences by 12.1% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 35,200 shares of the biopharmaceutical company’s stock worth $1,730,000 after purchasing an additional 3,800 shares during the period. 66.35% of the stock is owned by hedge funds and other institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Featured Story: Fundamental Analysis

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.